Search results for "Hep"

showing 10 items of 12243 documents

Diversity of extracellular vesicles from different developmental stages of Fasciola hepatica

2020

The secretion of extracellular vesicles (EVs) in Fasciola hepatica adult worms was described by our group in 2012. Since then, EVs have been found in other helminths, thus providing a new paradigm for the complete understanding of host-parasite communication. However, information was lacking regarding the possible existence and role of EVs from other developmental stages of the parasite. In this study, we confirm the secretion of EVs by F. hepatica eggs and juvenile forms. EVs were isolated by size exclusion chromatography and characterised by nanoparticle tracking analysis and electron microscopy. We observed a large diversity in the morphologies of these EVs, suggesting specific functions…

0301 basic medicineFuture studies030231 tropical medicineNanoparticle tracking analysisExtracellular vesicles03 medical and health sciencesExtracellular Vesicles0302 clinical medicineHepaticaSize exclusion chromatographyparasitic diseasesFasciola hepaticaParasite hostingAnimalsSecretionLife Cycle StagesbiologyVesicleFasciola hepaticaExtracellular vesiclesbiology.organism_classificationCell biology030104 developmental biologyInfectious DiseasesFasciola hepatica juvenilesParasitology
researchProduct

Use of deep learning methods to translate drug-induced gene expression changes from rat to human primary hepatocytes

2020

In clinical trials, animal and cell line models are often used to evaluate the potential toxic effects of a novel compound or candidate drug before progressing to human trials. However, relating the results of animal and in vitro model exposures to relevant clinical outcomes in the human in vivo system still proves challenging, relying on often putative orthologs. In recent years, multiple studies have demonstrated that the repeated dose rodent bioassay, the current gold standard in the field, lacks sufficient sensitivity and specificity in predicting toxic effects of pharmaceuticals in humans. In this study, we evaluate the potential of deep learning techniques to translate the pattern of …

0301 basic medicineGene ExpressionGene Expression Regulation/drug effectsPathology and Laboratory MedicineConvolutional neural networkTOXICITYMachine LearningVoeding Metabolisme en GenomicaTime Measurement0302 clinical medicineGene expressionMedicine and Health SciencesMeasurementClinical Trials as TopicMultidisciplinaryArtificial neural networkPharmaceuticsQRMetabolism and GenomicsTOXICOGENOMICS030220 oncology & carcinogenesisMetabolisme en GenomicaMedicineEngineering and TechnologyNutrition Metabolism and GenomicsHepatocytes/drug effectsAlgorithmsResearch ArticleComputer and Information SciencesClinical Trials as Topic/statistics & numerical dataNeural NetworksGenetic ToxicologyTOXICOLOGYSciencePredictive ToxicologyComputational biologyBiologyComputer03 medical and health sciencesDose Prediction MethodsDeep LearningVoedingArtificial IntelligenceIn vivoGeneticsLife ScienceAnimalsHumansGeneNutritionbusiness.industryDeep learningBiology and Life SciencesGold standard (test)REPRESENTATIONSRats030104 developmental biologyGene Expression RegulationHepatocytesArtificial intelligenceNeural Networks ComputerToxicogenomicsbusinessNeuroscience
researchProduct

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

2019

Background & Aims: Fibrosis progression (FP) after liver transplantation (LT) increases morbidity and mortality. Biomarkers are needed for early prediction of FP. A recipient’s seven-gene cirrhosis risk score (CRS) has been associated with FP, especially in non-transplant cohorts. A broader validation of CRS, including the genotype of the donor-organ and HCV-negative patients is lacking. We therefore analyzed the impact of donor- and recipient-specific genotypes on FP after LT in a large cohort of HCV-positive and -negative patients.Method: Genotyping from liver biopsies (n=201 donors) and peripheral blood (n=442 recipients) was performed. Cirrhosis risk score was correlated with FP at …

0301 basic medicineGenetic MarkersLiver CirrhosisMalemedicine.medical_specialtyCirrhosisTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisRisk FactorsInternal medicineGenotypeotorhinolaryngologic diseasesMedicineHumansCumulative incidenceGenetic Predisposition to DiseaseFramingham Risk Scorebusiness.industryHazard ratioGastroenterologyMiddle Agedmedicine.diseaseTissue DonorsLiver Transplantation030104 developmental biologyPhenotypeTreatment OutcomeDisease Progression030211 gastroenterology & hepatologyFemalebusinessRisk assessmentJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Data on the effects of low iron diet on serum lipid profile in HCV transgenic mouse model

2017

Here, we presented new original data on the effects of iron depletion on the circulating lipid profile in B6HCV mice, a murine model of HCV-related dyslipidemia. Male adult B6HCV mice were subjected to non-invasive iron depletion by low iron diet. Serum iron concentration was assessed for evaluating the effects of the dietary iron depletion. Concentrations of circulating triglycerides, total cholesterol, Low Density Lipoproteins (LDLs), High Density Lipoproteins (HDLs) were analyzed and reported by using stacked line charts. The present data indicated that low serum iron concentration is associated to i) lower serum triglycerides concentrations and ii) increased circulating LDLs. The presen…

0301 basic medicineGenetically modified mousemedicine.medical_specialtyLow density lipoproteins3304High densityLow density lipoproteinlcsh:Computer applications to medicine. Medical informaticsTriglyceride03 medical and health sciences0302 clinical medicineInternal medicinemedicineIron depletion; Low density lipoproteins; Triglycerides; 3304; MultidisciplinarySerum triglycerideslcsh:Science (General)TriglyceridesData ArticleDietary ironMultidisciplinarymedicine.diagnostic_testChemistrymedicine.diseaseIron depletion030104 developmental biologyEndocrinologyBiochemistrySerum ironlcsh:R858-859.7030211 gastroenterology & hepatologylipids (amino acids peptides and proteins)Lipid profileDyslipidemiaIron depletionlcsh:Q1-390Data in Brief
researchProduct

Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.

2016

A careful selection of the probiotic agent, standardization of the dose and detailed characterization of the beneficial effects are essential when considering use of a probiotic for the dietary management of serious diseases. However, changes in the manufacturing processes, equipment or facilities can result in differences in the product itself due to the live nature of probiotics. The need to reconfirm safety and/or efficacy for any probiotic product made at a different factory is therefore mandatory. Recently, under the brand VSL#3®, a formulation produced by a manufacturer different from the previous one, has been commercialized in some European countries (the UK and Holland). VSL#3 is a…

0301 basic medicineGenetics and Molecular Biology (all)Cell LinesCancer Treatmentlcsh:MedicineApoptosisMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Biochemistrylaw.inventionProbiotic0302 clinical medicinelawMedicine and Health SciencesMedicineCell Cycle and Cell DivisionEnzyme-Linked Immunoassayslcsh:ScienceStainingMultidisciplinaryCell DeathMedicine (all)Inflammatory Bowel DiseasesCell StainingApoptotic deathProbiotic agentOncologyCell Processes030211 gastroenterology & hepatologyBiological CulturesResearch ArticleTumor cellsAffect (psychology)Research and Analysis MethodsMicrobiology03 medical and health sciencesImmunoassaysBeneficial effectsBacteriabusiness.industryProbioticslcsh:ROrganismsBiology and Life SciencesCell BiologyIn vitroBiotechnology030104 developmental biologyAgricultural and Biological Sciences (all)Specimen Preparation and TreatmentImmunologyImmunologic Techniqueslcsh:QCaco-2 CellsbusinessPLoS ONE
researchProduct

Update on oral-facial-digital syndromes (OFDS)

2016

Oral-facial-digital syndromes (OFDS) represent a heterogeneous group of rare developmental disorders affecting the mouth, the face and the digits. Additional signs may involve brain, kidneys and other organs thus better defining the different clinical subtypes. With the exception of OFD types I and VIII, which are X-linked, the majority of OFDS is transmitted as an autosomal recessive syndrome. A number of genes have already found to be mutated in OFDS and most of the encoded proteins are predicted or proven to be involved in primary cilia/basal body function. Preliminary data indicate a physical interaction among some of those proteins and future studies will clarify whether all OFDS prote…

0301 basic medicineGeneticsCiliumOral facial digitalDevelopmental disorderDevelopmental disordersCell BiologyReviewBiologyBioinformaticsmedicine.diseasePhenotypeCiliopathiesHuman geneticsJoubert syndrome3. Good health03 medical and health sciences030104 developmental biologymedicineOFDSCiliaMeckel syndromeGene[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development.

2017

Summary Concomitant hepatocyte apoptosis and regeneration is a hallmark of chronic liver diseases (CLDs) predisposing to hepatocellular carcinoma (HCC). Here, we mechanistically link caspase-8-dependent apoptosis to HCC development via proliferation- and replication-associated DNA damage. Proliferation-associated replication stress, DNA damage, and genetic instability are detectable in CLDs before any neoplastic changes occur. Accumulated levels of hepatocyte apoptosis determine and predict subsequent hepatocarcinogenesis. Proliferation-associated DNA damage is sensed by a complex comprising caspase-8, FADD, c-FLIP, and a kinase-dependent function of RIPK1. This platform requires a non-apop…

0301 basic medicineGenome instabilityMaleliver; Hepatocellular carcinoma; DNA damage response; replication stress; apoptosisCancer ResearchDNA RepairCarcinogenesisFas-Associated Death Domain ProteinApoptosisurologic and male genital diseasesDNA damage responseDna Damage Response ; Apoptosis ; Hepatocellular Carcinoma ; Liver ; Replication StressHistonesMice0302 clinical medicineRisk FactorsFADDPhosphorylationCellular SenescenceCaspase 8biologyLiver Neoplasmshepatocellular carcinomaLiver regeneration3. Good healthHistoneOncologyReceptors Tumor Necrosis Factor Type I030220 oncology & carcinogenesisReceptor-Interacting Protein Serine-Threonine KinasesFemalebiological phenomena cell phenomena and immunityCell agingCarcinoma HepatocellularDNA damageDNA repairreplication stressCaspase 8liverArticleGenomic Instability03 medical and health sciencesAnimalsHepatectomyHumansCrosses GeneticCell ProliferationJNK Mitogen-Activated Protein KinasesCell BiologyLiver Regeneration030104 developmental biologyImmunologyChronic Diseasebiology.proteinCancer researchHepatocytesMyeloid Cell Leukemia Sequence 1 ProteinDNA Damage
researchProduct

Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.

2021

BACKGROUND & AIMS: Fatty liver disease (FLD) is a growing epidemic that is expected to be the leading cause of end-stage liver disease within the next decade. Both environmental and genetic factors contribute to the susceptibility of FLD. Several genetic variants contributing to FLD have been identified in exome-wide association studies. However, there is still a missing hereditability indicating that other genetic variants are yet to be discovered. METHODS: To find genes involved in FLD, we first examined the association of missense and nonsense variants with alanine amino transferase at an exome-wide level in 425,671 participants from the UK Biobank. We then validated genetic variants wit…

0301 basic medicineGenome-wide association studyLiver disease0302 clinical medicineENRICHMENT ANALYSISNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseExomeCONFERS SUSCEPTIBILITYGeneticsINSULIN-RESISTANCEmedicine.diagnostic_testFatty liverGastroenterologyAlanine Transaminase1-Acylglycerol-3-Phosphate O-Acyltransferase3. Good healthGENOMEEuropePhenotypeLiver biopsy030211 gastroenterology & hepatologyNonalcoholic Fatty Liver DiseaseMAFLDSingle-nucleotide polymorphismBiologyTransaminaseRisk Assessment03 medical and health sciencesApolipoproteins ENAFLDmedicineGenetic predispositionHumansGenetic Predisposition to DiseaseHEPATIC STEATOSISGenetic associationMAFLD Phenotype Reproducibility of Results Risk Assessment Risk Factors Transcriptome Genetic Variation Metabolic Associated Fatty Liver Disease Nonalcoholic Fatty Liver Disease Transaminase 1-Acylglycerol-3-Phosphate O-Acyltransferase Alanine Transaminase Apolipoproteins E Biomarkers Europe Exome Gene Expression Profiling Genetic Predisposition to Disease Genome-Wide Association Study Humans Non-alcoholic Fatty Liver DiseaseHepatologyMUTATIONSGene Expression ProfilingGenetic VariationReproducibility of Resultsmedicine.diseaseX-RECEPTORGENE030104 developmental biology3121 General medicine internal medicine and other clinical medicineMetabolic Associated Fatty Liver DiseaseRNA-SEQ DATATranscriptomePATHOGENICITYBiomarkersGenome-Wide Association StudyGastroenterology
researchProduct

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection

2016

Single-nucleotide polymorphisms near the interferon lambda 3 (IFNL3) gene predict outcomes to infection and anti-viral treatment in hepatitis C virus (HCV) infection. To identify IFNL3 genotype effects on peripheral blood, we collected phenotype data on 400 patients with genotype 1 chronic hepatitis C (CHC). The IFNL3 responder genotype predicted significantly lower white blood cells (WBCs), as well as lower absolute numbers of monocytes, neutrophils and lymphocytes for both rs8099917 and rs12979860. We sought to define the WBC subsets driving this association using flow cytometry of 67 untreated CHC individuals. Genotype-associated differences were seen in the ratio of CD4CD45RO+ to CD4CD4…

0301 basic medicineGenotypeTranscription FactorT-LymphocytesHepatitis C virusImmunologyHepacivirusBiologymedicine.disease_causeMonocyteMonocytesCohort Studies03 medical and health sciencesGeneticInterferonGenotypeGeneticsmedicineHumansGenetics (clinical)Whole bloodHepaciviruInterleukinsMonocyteGATA3Hepatitis CHepatitis C ChronicInterleukinViral Loadmedicine.diseaseFlow CytometryAntigens Differentiation3. Good healthKiller Cells Natural030104 developmental biologymedicine.anatomical_structureT-LymphocyteImmunologyOriginal ArticleInterferonsCohort StudieViral loadTranscription Factorsmedicine.drugHuman
researchProduct

Viral resistance in HCV infection.

2018

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review…

0301 basic medicineGenotypeTreatment outcomeDrug ResistanceDrug resistanceHepacivirusBiologyViral resistanceAntiviral AgentsVirological response03 medical and health sciences0302 clinical medicinePharmacotherapyDrug TherapyDrug Resistance Multiple ViralVirologyRibavirinmedicineHumansGenetic variabilityViralTreatment FailureChronicAntiviral Agents; Drug Therapy Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance Multiple ViralGenetic VariationHepatitis CHepatitis C Chronicmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis C030104 developmental biologyHCVImmunologyCombinationHcv treatment030211 gastroenterology & hepatologyDrug Therapy CombinationInterferonsMultipleCurrent opinion in virology
researchProduct